バイオシミラーモノクローナル抗体の世界市場:種類別(合成化学物質、バイオ医薬品、その他)、用途別(慢性、自己免疫疾患、腫瘍、その他)、地域別

◆英語タイトル:Global Biosimilar Monoclonal Antibody Market Size study, by Type (Synthetic Chemicals, Biopharmaceuticals and Others), By Application (Chronic & Autoimmune Diseases, Oncology and Others) and Regional Forecasts 2019-2026
◆商品コード:BZW20AP032
◆発行会社(リサーチ会社):Bizwit Research & Consulting
◆発行日:2020年4月22日
◆ページ数:約200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥650,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はBizwit Research & Consulting社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Bizwit Research & Consulting社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、バイオシミラーモノクローナル抗体の世界市場について、エグゼクティブサマリー、市場の定義・範囲、市場動向、産業分析、種類別(合成化学物質、バイオ医薬品、その他)分析、用途別(慢性、自己免疫疾患、腫瘍、その他)分析、地域別分析、競争状況などを総合的、多面的に調査・分析しております。
・エグゼクティブサマリー
・市場の定義・範囲
・市場動向
・産業分析
・バイオシミラーモノクローナル抗体の世界市場:種類別(合成化学物質、バイオ医薬品、その他)
・バイオシミラーモノクローナル抗体の世界市場:用途別(慢性、自己免疫疾患、腫瘍、その他)
・バイオシミラーモノクローナル抗体の世界市場:地域別
・競争状況
【レポートの概要】

Global Biosimilar Monoclonal Antibody Market is valued approximately at USD 27.84 Billion in 2018 and is anticipated to grow with a healthy growth rate of more than 35.70% over the forecast period 2019-2026. Biosimilar monoclonal antibodies can be known as a biological molecule derived by the organisms and living cells. Also, it displays a certain level of variability which can be attributed to the variations in the biological expression systems of the recombinant. In addition, biosimilar monoclonal antibodies are widely used in various fields of diagnostics of diseases such as oncology, autoimmune and in various chronic diseases. The Biosimilar Monoclonal Antibody market to witness prominent growth owing to the incorporation of advanced mAbs (Monoclonal Antibodies). As a result, the demand & adoption for Biosimilar Monoclonal Antibody would increase thereby, making its way for the growth of the market. The growth of the market is primarily driven by the increase in prevalence of diseases, such as cancer and rheumatoid arthritis and growth in geriatric population globally. For Instance: according to World Cancer Research Fund International (WCRFI), breast cancer is the most common form of cancer in women worldwide with an average 2million new cases being detected every year. American Cancer Research Society (ACRS) anticipates by 2030, incident rate of breast cancer is expected to reach over 9.9million cases with over 5.5million annual deaths, primarily due to aging population. Similarly, as per the European Breast Cancer Coalition, incidence in the EU-28 in 2018 was estimated to be around 404,920. Thus, the demand for biosimilar monoclonal antibodies would increase as these drugs are normally administered in the treatment of cancer, chronic lymphocytic and leukemia. However, unfavorable government regulations in developed regions along with the high cost associated with the manufacturing process of these drugs are expected to impede the growth of the market over the forecast period.

The regional analysis of global Biosimilar Monoclonal Antibody market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is expected to hold a notable share in the world in terms of revenue owing to the presence of advanced healthcare facilities along with the increasing adoption of biosimilar monoclonal antibodies. The dominance of the region is witnessed owing to the ongoing government activities to develop advanced and novel drugs. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period. Factors such as rising public-private initiative aimed towards boosting advance research practices and increase investment to promote Biosimilar Monoclonal Antibody research is expected to create lucrative prospects for the growth pf the region during the forecast period of 2019-2026.

Major market player included in this report are:
Allergan plc
BIOCAD BioXpress
Therapeutics SA
Biocon Limited
Boehringer Ingelheim GmbH
Celltrion Inc
Coherus BioSciences Inc
Dr. Reddys Laboratories Ltd
Genor BioPharma Co Ltd
Intas Pharmaceuticals Limited

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Synthetic Chemicals
Biopharmaceuticals
Others

By Application:
Chronic & Autoimmune Diseases
Oncology
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Global Biosimilar Monoclonal Antibody Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

【レポートの目次】

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2017-2026 (USD Billion)
1.2.1. Biosimilar Monoclonal Antibody Market, by Region, 2017-2026 (USD Billion)
1.2.2. Biosimilar Monoclonal Antibody Market, by Type, 2017-2026 (USD Billion)
1.2.3. Biosimilar Monoclonal Antibody Market, by Application, 2017-2026 (USD Billion)
1.2.4. Biosimilar Monoclonal Antibody Market, by End-User, 2017-2026 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Biosimilar Monoclonal Antibody Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Biosimilar Monoclonal Antibody Market Dynamics
3.1. Biosimilar Monoclonal Antibody Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Biosimilar Monoclonal Antibody Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Biosimilar Monoclonal Antibody Market, by Type
5.1. Market Snapshot
5.2. Global Biosimilar Monoclonal Antibody Market by Type, Performance – Potential Analysis
5.3. Global Biosimilar Monoclonal Antibody Market Estimates & Forecasts by Type, 2016-2026 (USD Billion)
5.4. Biosimilar Monoclonal Antibody Market, Sub Segment Analysis
5.4.1. Synthetic Chemicals
5.4.2. Biopharmaceuticals
5.4.3. Others
Chapter 6. Global Biosimilar Monoclonal Antibody Market, by Application
6.1. Market Snapshot
6.2. Global Biosimilar Monoclonal Antibody Market by Application, Performance – Potential Analysis
6.3. Global Biosimilar Monoclonal Antibody Market Estimates & Forecasts by Application 2016-2026 (USD Billion)
6.4. Biosimilar Monoclonal Antibody Market, Sub Segment Analysis
6.4.1. Chronic & Autoimmune Diseases
6.4.2. Oncology
6.4.3. Others
Chapter 7. Global Biosimilar Monoclonal Antibody Market, Regional Analysis
7.1. Biosimilar Monoclonal Antibody Market, Regional Market Snapshot
7.2. North America Biosimilar Monoclonal Antibody Market
7.2.1. U.S. Biosimilar Monoclonal Antibody Market
7.2.1.1. Type breakdown estimates & forecasts, 2016-2026
7.2.1.2. Application Industry breakdown estimates & forecasts, 2016-2026
7.2.2. Canada Biosimilar Monoclonal Antibody Market
7.3. Europe Biosimilar Monoclonal Antibody Market Snapshot
7.3.1. U.K. Biosimilar Monoclonal Antibody Market
7.3.2. Germany Biosimilar Monoclonal Antibody Market
7.3.3. Rest of Europe Biosimilar Monoclonal Antibody Market
7.4. Asia-Pacific Biosimilar Monoclonal Antibody Market Snapshot
7.4.1. China Biosimilar Monoclonal Antibody Market
7.4.2. India Biosimilar Monoclonal Antibody Market
7.4.3. Japan Biosimilar Monoclonal Antibody Market
7.4.4. Rest of Asia Pacific Biosimilar Monoclonal Antibody Market
7.5. Latin America Biosimilar Monoclonal Antibody Market Snapshot
7.5.1. Brazil Biosimilar Monoclonal Antibody Market
7.5.2. Mexico Biosimilar Monoclonal Antibody Market
7.6. Rest of The World Biosimilar Monoclonal Antibody Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Allergan plc
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. BIOCAD BioXpress
8.2.3. Therapeutics SA,
8.2.4. Biocon Limited
8.2.5. Boehringer Ingelheim GmbH
8.2.6. Celltrion Inc
8.2.7. Coherus BioSciences Inc
8.2.8. Dr. Reddys Laboratories Ltd
8.2.9. Genor BioPharma Co Ltd
8.2.10. Intas Pharmaceuticals Limited
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET
TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, REPORT SCOPE
TABLE 4. YEARS CONSIDERED FOR THE STUDY
TABLE 5. EXCHANGE RATES CONSIDERED
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY TYPE 2016-2026 (USD BILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY APPLICATION 2016-2026 (USD BILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY END-USER 2016-2026 (USD BILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 21. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 22. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 23. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 24. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 25. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 26. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 27. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 28. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 29. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 30. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 31. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 32. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 33. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 34. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 35. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 36. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 37. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 38. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 39. ROE BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 40. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 41. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 42. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 43. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 44. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 45. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 46. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 47. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 48. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 49. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 50. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 51. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 52. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 53. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 54. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 55. ROAPAC BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 56. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 57. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 58. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 59. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 60. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 61. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 63. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 64. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 65. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 66. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 67. ROLA BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 68. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 69. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 70. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 71. ROW BIOSIMILAR MONOCLONAL ANTIBODY MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

FIG 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, KEY TRENDS 2018
FIG 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, GROWTH PROSPECTS 2019-2026
FIG 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, PEST ANALYSIS
FIG 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, REGIONAL SNAPSHOT 2016 & 2026
FIG 16. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 17. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 18. ASIA PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 19. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET 2016 & 2026 (USD BILLION)
FIG 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, COMPANY MARKET SHARE ANALYSIS (2018)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[バイオシミラーモノクローナル抗体の世界市場:種類別(合成化学物質、バイオ医薬品、その他)、用途別(慢性、自己免疫疾患、腫瘍、その他)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆